Clinical trial
A Two-Stage Phase 1 Open-Label Study of huJCAR014, CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells Bearing a Human Binding Domain, in Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Acute Lymphocytic Leukemia
NCT03103971 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Two-Stage Phase 1 Open-Label Study of huJCAR014, CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells Bearing a Human Binding Domain, in Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Acute Lymphocytic Leukemia
- Lead sponsor
- Fred Hutchinson Cancer Center
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- November 3, 2017
- Completion date
- March 23, 2024
- Enrollment
- 55 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
recurrent adult acute lymphoblastic leukemia, recurrent b acute lymphoblastic leukemia, recurrent b-cell non-hodgkin lymphoma, recurrent diffuse large b-cell lymphoma, recurrent diffuse large b-cell lymphoma, not otherwise specified, recurrent high grade b-cell lymphoma with myc and bcl2 or bcl6 rearrangements, recurrent high grade b-cell lymphoma with myc, bcl2, and bcl6 rearrangements, recurrent primary mediastinal (thymic) large b-cell lymphoma, recurrent transformed non-hodgkin lymphoma, refractory adult acute lymphoblastic leukemia, refractory b acute lymphoblastic leukemia, refractory b-cell non-hodgkin lymphoma, refractory diffuse large b-cell lymphoma, refractory diffuse large b-cell lymphoma, not otherwise specified, refractory high grade b-cell lymphoma with myc and bcl2 or bcl6 rearrangements, refractory high grade b-cell lymphoma with myc, bcl2, and bcl6 rearrangements, refractory primary mediastinal (thymic) large b-cell lymphoma